4893 Stock Overview
Noile-Immune Biotech Inc. researches and develops CAR-T cells for cancer immunotherapies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Noile-Immune Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥162.00 |
| 52 Week High | JP¥775.00 |
| 52 Week Low | JP¥150.00 |
| Beta | 0 |
| 1 Month Change | -13.83% |
| 3 Month Change | -14.29% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.34% |
Recent News & Updates
Shareholder Returns
| 4893 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 4.5% | 2.4% | 0.8% |
| 1Y | n/a | -24.1% | 26.5% |
Return vs Industry: Insufficient data to determine how 4893 performed against the JP Biotechs industry.
Return vs Market: Insufficient data to determine how 4893 performed against the JP Market.
Price Volatility
| 4893 volatility | |
|---|---|
| 4893 Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.2% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 4893's share price has been volatile over the past 3 months.
Volatility Over Time: 4893's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 28 | Koji Tamada | www.noile-immune.com |
Noile-Immune Biotech Inc. researches and develops CAR-T cells for cancer immunotherapies. The company was incorporated in 2015 and is headquartered in Minato, Japan.
Noile-Immune Biotech Inc. Fundamentals Summary
| 4893 fundamental statistics | |
|---|---|
| Market cap | JP¥7.49b |
| Earnings (TTM) | -JP¥1.13b |
| Revenue (TTM) | JP¥316.00m |
22.2x
P/S Ratio-6.2x
P/E RatioIs 4893 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4893 income statement (TTM) | |
|---|---|
| Revenue | JP¥316.00m |
| Cost of Revenue | JP¥42.00m |
| Gross Profit | JP¥274.00m |
| Other Expenses | JP¥1.40b |
| Earnings | -JP¥1.13b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -26.10 |
| Gross Margin | 86.71% |
| Net Profit Margin | -357.59% |
| Debt/Equity Ratio | 0% |
How did 4893 perform over the long term?
See historical performance and comparison